Clinical Scorecard: Caribou Plans to Discontinue Allogeneic CAR T Programs Amid Funding Pressures
At a Glance
| Category | Detail |
|---|---|
| Condition | Vispa-cel is being developed for relapsed or refractory B-cell non-Hodgkin lymphoma; CB-011 is being evaluated for relapsed or refractory multiple myeloma. |
| Key Mechanisms | Vispa-cel is an anti-CD19 CAR T-cell therapy with a PD-1 knockout intended to limit premature T-cell exhaustion. CB-011 is an anti-BCMA therapy with a B2M knockout and insertion of a B2M–HLA-E-peptide fusion protein intended to reduce immune rejection of donor-derived cells. |
| Target Population | Vispa-cel targets patients with relapsed or refractory B-cell non-Hodgkin lymphoma; CB-011 is being evaluated in patients with relapsed or refractory multiple myeloma. |
| Care Setting | Clinical development of investigational cell therapies; the article reports no treatment use or care-setting recommendations. |
Key Highlights
- Caribou plans to discontinue development of vispa-cel and CB-011 and make substantial workforce reductions.
- The company cited difficulty securing funding in the current financing environment for allogeneic CAR T-cell therapies.
- Vispa-cel had reached agreement with the FDA on the design of a pivotal phase III trial; CB-011 was being evaluated in relapsed or refractory multiple myeloma.
- Both candidates received FDA Regenerative Medicine Advanced Therapy, Fast Track, and Orphan Drug designations.
- Caribou’s board is reviewing strategic alternatives, including a possible merger, acquisition, business combination, or transaction involving the company or its assets.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Vispa-cel was being developed for relapsed or refractory B-cell non-Hodgkin lymphoma; CB-011 was being evaluated for relapsed or refractory multiple myeloma.
The article describes allogeneic CAR T-cell therapies as using donor cells. Caribou plans no further development of these candidates under its current plans; the article provides no prescribing or dosing information.
Clinical Best Practices
- The article provides no clinical best-practice recommendations.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
